← back to search

Luke Howard

Imperial College Healthcare NHS Trust · GB
Area of research
Pulmonary and Respiratory Medicine · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Pulmonary Hypertension Research and Treatments, Cardiovascular Function and Risk Factors, Chronic Obstructive Pulmonary Disease (COPD) Research, and Venous Thromboembolism Diagnosis and Management.
h-index
70
citations
23,272
works
534
NIH funding
primary concept
Medicine
email

Recent publications

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study
International Journal of Infectious Diseases 2026cited by 1position: middledoi
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis
American Journal of Respiratory and Critical Care Medicine 2025cited by 8position: middledoi
Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment
EBioMedicine 2025cited by 2position: middledoi
Lower Airway and Oral Microbiome Dysbiosis in Patients with Long COVID Post-Hospitalisation: A UK Multicentre, Prospective Cohort Study
SSRN Electronic Journal 2025cited by 0position: middledoi
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
Nature Immunology 2024cited by 91position: middledoi
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
The Lancet Respiratory Medicine 2024cited by 60position: middledoi
Management of pulmonary hypertension in special conditions
European Respiratory Journal 2024cited by 37position: middledoi
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
The Lancet Respiratory Medicine 2024cited by 33position: middledoi
Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies
European Respiratory Journal 2024cited by 7position: middledoi
1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study
ERJ Open Research 2024cited by 2position: middledoi
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
Genetics in Medicine 2023cited by 70position: middledoi
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
The Lancet Respiratory Medicine 2023cited by 32position: middledoi
Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study
International Journal of Epidemiology 2023cited by 17position: middledoi
Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)
medRxiv 2023cited by 6position: middledoi
One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study
medRxiv 2023cited by 1position: middledoi
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
EBioMedicine 2022cited by 121position: middledoi
Imaging the right atrium in pulmonary hypertension: A systematic review and meta-analysis
The Journal of Heart and Lung Transplantation 2022cited by 32position: middledoi
Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension
The Journal of Heart and Lung Transplantation 2022cited by 27position: middledoi
Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19
ERJ Open Research 2022cited by 25position: middledoi
Cardiopulmonary disease as sequelae of long-term COVID-19: Current perspectives and challenges
Frontiers in Medicine 2022cited by 11position: middledoi
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
The Lancet Respiratory Medicine 2021cited by 648position: middledoi
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
European Respiratory Journal 2021cited by 88position: middledoi
Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH
Genome Medicine 2021cited by 84position: middledoi
Physical, cognitive and mental health impacts of COVID-19 following hospitalisation – a multi-centre prospective cohort study
medRxiv 2021cited by 67position: middledoi
Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
Nature Communications 2021cited by 54position: middledoi
Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
medRxiv 2021cited by 21position: middledoi
Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure
Circulation 2020cited by 304position: middledoi
Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1)
JACC: Cardiovascular Interventions 2020cited by 78position: middledoi
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome
American Journal of Respiratory and Critical Care Medicine 2020cited by 72position: middledoi
Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension
Circulation Genomic and Precision Medicine 2020cited by 46position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Francesco Lo Giudice · Imperial College Healthcare NHS Trust3 papers (2020–2022)Roberto Badagliacca · University of Naples Federico II2 papers (2022–2022)David G. Kiely · Istituti di Ricovero e Cura a Carattere Scientifico2 papers (2012–2020)Davide Stolfo · May Institute2 papers (2020–2022)Hossein Ardeschir Ghofrani · Justus-Liebig-Universität Gießen2 papers (2012–2022)Carmine Dario Vizza · The Ohio State University Wexner Medical Center2 papers (2022–2022)François Haddad · Stanford University1 papers (2022–2022) · 1 papers (2022–2022)Ehtisham Mahmud · Minneapolis Heart Institute Foundation1 papers (2020–2020)Nick H. Kim · UC San Diego Health System1 papers (2020–2020)Lewis J. Rubin · University of California San Diego1 papers (2020–2020)Konstantinos Dimopoulos · St Thomas' Hospital1 papers (2014–2014) · 1 papers (2022–2022)С. Н. Авдеев · Peoples' Friendship University of Russia1 papers (2022–2022)Ana Olga Mocumbi · Eduardo Mondlane University1 papers (2022–2022)Alexander Rothman · University of Minnesota1 papers (2020–2020) · 1 papers (2020–2020)Ioana R. Preston · Actelion (Switzerland)1 papers (2024–2024) · 1 papers (2022–2022)Rocco Francesco Rinaldo · Imperial College Healthcare NHS Trust1 papers (2022–2022)